• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider George Dan

    4/28/25 5:23:28 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    George Dan

    (Last) (First) (Middle)
    C/O ADAGIO MEDICAL HOLDINGS, INC.
    26051 MERIT CIRCLE, STE. 102

    (Street)
    LAGUNA HILLS CA 92653

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/17/2025
    3. Issuer Name and Ticker or Trading Symbol
    Adagio Medical Holdings, Inc. [ ADGM ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    No securities are beneficially owned.
    /s/ Daniel George 04/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADGM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Adagio Medical Holdings Inc

      424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

      5/15/25 4:58:47 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Adagio Medical Holdings Inc

      424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

      5/15/25 4:58:30 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

      SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)

      5/15/25 4:48:19 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagio Medical Reports First Quarter 2025 Results

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug Administration (the "FDA") for the vCLAS™ Cryoablation System ("vCLAS"), for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ("VT") in patients with ischemic or non-ischemic structural heart disease. The vCLASTM Cryoablation System is currently the subject of the FULCRUM-VT Investigational Device Exemption (

      5/15/25 4:05:00 PM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Adagio Medical to Present at the BofA Securities 2025 Health Care Conference

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. Presentation Information A live and recorded webcast of the presentation will be available at: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id5FQ7Pq.cfm About Adagio Medical Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietar

      5/7/25 8:30:00 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care
    • Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System

      Agency's Breakthrough Device Designation Program Allows for Priority Review of Ablation Technology for Ventricular Tachycardia Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration ("FDA") for its vCLASTM Cryoablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ("VT") in patients with ischemic or non-ischemic structural heart disease. Adagio's vCLASTM Cryoablation System, which is currently the subject of an I

      4/17/25 8:30:00 AM ET
      $ADGM
      Medical/Dental Instruments
      Health Care